Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsGilles Tamagnan, PhD
Associate Professor Adjunct, PsychiatryAbout
Copy Link
Titles
Associate Professor Adjunct, Psychiatry
Departments & Organizations
Education & Training
- PhD
- University Joseph Pourier (1993)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Gilles Tamagnan's published research.
Publications Timeline
A big-picture view of Gilles Tamagnan's research output by year.
John Seibyl, MD
Irina Esterlis, PhD
David S. Russell, MD, PhD
Kelly Cosgrove, PhD
Edward Belk Perry Jr, MD, MHS
Christopher van Dyck, MD
99Publications
1,433Citations
Publications
2025
Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates
Gravel P, Gu J, Wang C, Volpi T, Gallezot J, Holden D, Fowles K, Zheng M, Zhang L, Borroni E, Honer M, Gobbi L, Tamagnan G, Huang Y, Carson R. Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates. Journal Of Nuclear Medicine 2025, 66: 1652-1658. PMID: 40908122, PMCID: PMC12487869, DOI: 10.2967/jnumed.125.270332.Peer-Reviewed Original ResearchAltmetricConceptsGABA transporter type 1Nonhuman primatesGAT-1Brain uptakeNondisplaceable binding potentialSubcortical gray matter regionsHuman studiesG-aminobutyric acidLow brain uptakeGray matter structuresLow specific bindingConclusion:Methods:Gray matter regionsType 1Results:Neuropsychiatric disordersPET radiotracersBinding potentialGABA signalingVolume of distributionMatter structuresRhesus monkeysBlock scanningGABA receptors
2024
Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy
Ma J, Dong C, Qiao H, Barret O, Tamagnan G, Mao W, Xu E, Zhang C, Lu J, Chan P, Liu S. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy. Movement Disorders 2024, 39: 847-854. PMID: 38477228, DOI: 10.1002/mds.29769.Peer-Reviewed Original ResearchCitationsAltmetricConceptsVesicular monoamine transporter 2Vesicular monoamine transporter 2 bindingProgressive supranuclear palsy groupPositron emission tomographyProgressive supranuclear palsyHealthy controlsParkinson's diseaseStriatal VMAT2 bindingMonoamine transporter 2Mini-Mental State ExaminationNucleus accumbensMontreal Cognitive AssessmentVMAT2 bindingRating ScaleCognitive AssessmentSubstantia nigraMini-MentalSupranuclear palsyState ExaminationProgressive Supranuclear Palsy Rating ScaleHippocampusPET/Computed TomographyPD groupClinical characteristicsStriatum
2023
18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease
Huang A, Liu S, Barret O, Qiao H, Tamagnan G, Liu X, Fan C, Li Z, Lu J, Chan P, Xu E. 18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease. Parkinsonism & Related Disorders 2023, 120: 105979. PMID: 38241952, DOI: 10.1016/j.parkreldis.2023.105979.Peer-Reviewed Original ResearchCitationsConceptsPostural instability gait difficultyMotor subtypesParkinson's diseaseStandardized uptake value ratioDifferent motor subtypesStriatal dopaminergic depletionParkinsonian motor symptomsUptake value ratioPET/CTDopaminergic disruptionMonoaminergic depletionMonoaminergic changesDopaminergic depletionMotor symptomsPIGD scoresDorsal putamenPD subtypesVentral putamenPD pathogenesisPrognosis evaluationPatientsDominant subtypeMethods SixtyAccurate diagnosisDifferent subtypes
2018
IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY
Stephens A, Seibyl J, Mueller A, Barret O, Berndt M, Madonia J, Kroth H, Bullich S, Pfeifer A, Muhs A, Tamagnan G, Marek K, Dinkelborg L. IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY. Alzheimer's & Dementia 2018, 14: p179-p179. DOI: 10.1016/j.jalz.2018.06.2287.Peer-Reviewed Original ResearchCitationsP1‐400: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION
Tempest P, Ono M, Higuchi M, Shimada H, Suhara T, Zhang M, Tai C, Carroll V, Tamagnan G, Marek K, Barret O, Alagille D, Jang M. P1‐400: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. Alzheimer's & Dementia 2018, 14: p455-p455. DOI: 10.1016/j.jalz.2018.06.408.Peer-Reviewed Original ResearchIC‐P‐082: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION
Tempest P, Ono M, Higuchi M, Shimada H, Suhara T, Tai C, Tamagnan G, Carroll V, Alagille D, Barret O, Marek K, Jang M. IC‐P‐082: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. Alzheimer's & Dementia 2018, 14: p71-p71. DOI: 10.1016/j.jalz.2018.06.2146.Peer-Reviewed Original ResearchEvaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals (P5.263)
Koike T, Miyamoto M, Nishi T, Sunahara E, Hasegawa S, Watanabe S, Ikeda S, Ishii T, Kondo S, Takahashi J, Hirabayashi H, Alagille D, Barret O, Tamagnan G, Kuroita T. Evaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals (P5.263). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p5.263.Peer-Reviewed Original ResearchCitationsT156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
Tamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, McCarthy T, Zhang L, Gray D, Villalobos A, Lee C, Chen J, Seibyl J, Marek K. T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN. Schizophrenia Bulletin 2018, 44: s176-s176. PMCID: PMC5888516, DOI: 10.1093/schbul/sby016.432.Peer-Reviewed Original ResearchCitationsConceptsLogan graphical analysisNon-human primatesRhesus monkeysD1 receptorsBlockade studiesPET studiesPET radiotracersD1 receptor occupancyWhole-brain uptakeNovel PET radiotracersInhibitory G proteinSame dose levelMin post injectionHealthy human volunteersTest-retest reproducibilityBrain PET studiesPET imaging tracerAgonist PET tracerClinical studiesStriatal regionsInjected dosePsychiatric disordersCerebellar cortexDose levelsReceptor occupancy
2017
[IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES
Mueller A, Kroth H, Schieferstein H, Berndt M, Oden F, Capotosti F, Molette J, Juergens T, Darmency V, Schmitt‐Willich H, Hickman D, Tamagnan G, Pfeifer A, Dinkelborg L, Muhs A, Stephens A. [IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. Alzheimer's & Dementia 2017, 13: p141-p142. DOI: 10.1016/j.jalz.2017.06.2567.Peer-Reviewed Original ResearchCitations[IC‐P‐198]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3
Shimada H, Kitamura S, Ono M, Kimura Y, Ichise M, Takahata K, Moriguchi S, Kubota M, Ishii T, Takado Y, Seki C, Hirano S, Shinotoh H, Sahara N, Tempest P, Tamagnan G, Seibyl J, Barret O, Alagille D, Zhang M, Kuwabara S, Jang M, Marek K, Suhara T, Higuchi M. [IC‐P‐198]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3. Alzheimer's & Dementia 2017, 13: p146-p146. DOI: 10.1016/j.jalz.2017.06.2573.Peer-Reviewed Original ResearchCitations
Get In Touch
Copy Link